Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain gene injection aims to halt rare childhood disease

NCT ID NCT01801709

First seen Nov 18, 2025 · Last updated Jun 23, 2026 · Updated 25 times

Summary

This study tested a gene therapy for children with early-onset metachromatic leukodystrophy (MLD), a rare and severe brain disease. Five children aged 6 months to 5 years received direct injections of a harmless virus carrying a working gene into their brains. The goal was to see if it is safe and can slow disease progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METACHROMATIC LEUKODYSTROPHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Bicêtre Hospital - Paris Sud

    Le Kremlin-Bicêtre, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

AAVrh.10cuARSA gene therapy

What this could lead to

If it works, this could slow or stop the progression of metachromatic leukodystrophy in young children, potentially preserving brain function.

What could go wrong

This is a very early, small trial (only 5 children) testing safety first. The treatment involves direct brain injections, which carries risks like bleeding or infection. It may not stop the disease.

Conditions

The condition(s) this trial relates to.

metachromatic leukodystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.